Deutsche Bank Raises PT on Gilead Sciences (GILD); Expect Approval of Quad on 8/27 Followed by Strong Launch

August 15, 2012 7:37 AM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $106.74 +1.14%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 25 | New: 50
Trade GILD Now!
Join SI Premium – FREE
Deutsche Bank maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $68.00 (from $65.00).

Analyst, Robyn Karnauskas, said, "We believe approval is almost certain due to positive FDA panel in May & Quad already being added to US HIV treatment guidelines...Mgmt says Quad launch will be stronger than Complera, but weaker than Atripla. Atripla sold $206M in ‘06 & Complera $49M in ’11...We expect pricing at a ~19-30% premium to Complera since Quad is more convenient than both Isentress & boosted PI markets and less tox than Atripla...In EU, Atripla is first line therapy although it sold $1B in 2011. Pro-Viread data will readout Q412, which may extend Viread patent if better than Viread."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $57.57 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Deutsche Bank

Add Your Comment